Lundbeck

Pharma

Copenhagen, Denmark, Denmark · Est. 1915 · 8,200 employees

Lundbeck is a Danish pharmaceutical company focused on developing and commercializing innovative treatments for psychiatric and neurological disorders.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

244

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 2 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

4 drugs in development

Phase 31

Phase 22

Phase 12

By Therapeutic Area

top 3

Neurology

233%

Metabolic & Endocrine

233%

Ophthalmology

233%

R&D Momentum

54/100

Pipeline Velocity

15/100

Trial Completion Rate

81/100

Pipeline Concentration

33/100

Pipeline Freshness

75/100

Strategic Signals

↗Early-stage heavy pipeline may seek late-stage partners
↗Active in Neurology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 10, 2026

Recruiting

Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Eptinezumab in Paediatric Patients (6 to 17 Years) for the Preventive Treatment of Episodic Migraine

Sep 10, 2026

Active, not recruiting

Interventional, Open-label, Single-group, Long-term Follow-up Trial of Lu AG22515 in Patients With Moderate-to-severe Thyroid Eye Disease

Sep 10, 2026

Completed

Interventional, Open-label Trial, Investigating the Effectiveness of Eptinezumab in Participants With Migraine and Previous Inadequate Response to CGRP-targeting Therapies

Sep 9, 2026

Recruiting

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose Trial of Lu AF28996 in Adults With Parkinson's Disease Experiencing Motor Fluctuations

Earlier

Aug 22, 2026TrialA Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease

Aug 22, 2026TrialInterventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of IV Eptinezumab in Adolescents (12-17 Years) for the Preventive Treatment of Chronic Migraine

Aug 21, 2026TrialInterventional, Open-label, Fixed-sequence Crossover Trial Investigating the Effect of CYP3A4/5 Modulation on the Pharmacokinetics, Safety and Tolerability of Lu AH69593 and the Effect of Lu AH69593 on the Pharmacokinetics of a CYP3A4/5 Substrate in Healthy Participants

Aug 13, 2026TrialInterventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single- and Multiple-ascending-dose Trial Investigating Safety, Tolerability, and Pharmacokinetics of Lu AH69593 in Healthy Participants, Including Open-label Cohorts to Explore Pharmacodynamic Properties in Participants With Narcolepsy, and Food Effect in Healthy Participants

4 more events

Aug 11, 2026TrialInterventional, Open-label, Trial Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AF28996 in Chinese Men and Women With Parkinson's Disease

Jul 15, 2026TrialInterventional, Randomized, Double-blind, Placebo-controlled, Optional Open-label Extension Trial of Lu AF82422 in Participants With Multiple System Atrophy

Jun 5, 2026FDAVyepti — VYEPTI

Mar 18, 2026TrialPROMISE-3: Eptinezumab in Medication-Overuse Headache

Details

Company Info

Company Overview

$9.5B

Mkt Cap

$2.2B

Revenue

—

Cash

CEODeborah Dunsire

Founded1915

Employees8,200

HQCopenhagen, Denmark, Denmark

Websitelundbeck.com

LinkedInCompany Page

Therapeutic Focus

psychiatryneurologypain managementaddiction

Patent Expirations

5 patent groups across drugs · Source: FDA Orange Book

DrugExpires

SabrilAug 16, 2039 Sympazan2 patentsSep 5, 2039 SympazanJan 31, 2040 SabrilOct 17, 2042 SabrilJun 8, 2043

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Regulatory

Regulatory Timeline

19841 event

FDAMay 14

Winstrol — WINSTROL

Application NDA012885 (NDA)

20092 events

FDAAug 21

Sabril — SABRIL

Application NDA022006 (NDA)

FDAAug 21

Sabril — SABRIL

Application NDA020427 (NDA)

20111 event

FDAOct 21

Sympazan — ONFI

Application NDA202067 (NDA)

20121 event

FDADec 14

Sympazan — ONFI

Application NDA203993 (NDA)

20141 event

FDAFeb 18

Northera — NORTHERA

Application NDA203202 (NDA)

20181 event

FDANov 1

Sympazan — SYMPAZAN

Application NDA210833 (NDA)

20202 events

FDAFeb 21

Vyepti — VYEPTI

Application BLA761119

FDAFeb 21

Vyepti — VYEPTI

Application BLA761119 (BLA)

20211 event

FDASep 24

Vyepti — VYEPTI

Application BLA761119

20221 event

FDAOct 21

Vyepti — VYEPTI

Application BLA761119

20241 event

FDAJun 17

Sabril — VIGAFYDE

Application NDA217684 (NDA)

20254 events

FDAOct 22

Vyepti — VYEPTI

Application BLA761119

FDAAug 18

Vyepti — VYEPTI

Application BLA761119

FDAMar 21

Vyepti — VYEPTI

Application BLA761119

FDAMar 21

Vyepti — VYEPTI

Application BLA761119

20261 event

FDAJun 5

Vyepti — VYEPTI

Application BLA761119

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)